Silence Therapeutics (SLN) Welcomes Tim McInerney to Board of Directors

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company’s Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting (“AGM”) in June 2025.

“We are thrilled to welcome Tim to the Silence Board,” said Iain Ross, Chairman of the Silence Board. “Tim is a seasoned executive and board member with extensive experience in both the investment and pharmaceutical industries. We look forward to his guidance as we continue our evolution towards the U.S. markets while positioning Silence as a global siRNA leader.”

Tim McInerney brings over 30 years of experience as a pharmaceutical executive and healthcare investment banker/analyst with positions in industry and a number of Wall Street firms. Following positions at Bristol Myers, Bear Stearns and Ladenburg Thalmann, Tim oversaw the overall distribution of Paramount Biocapital's private equity product and was directly responsible for capital raised for both startups and private placement investments in the healthcare sector. In the early-stage financings of Cougar Biotech (acquired by J&J), Kite Pharma (acquired by Gilead), Velcera (acquired by Perrigo) and Ziopharm Oncology, Tim played a significant role. He has served on numerous public and private boards including as chairman of Insite Vision (acquired by Sun Pharmaceuticals) and Edgemont Pharmaceuticals (acquired by Alvogen,Inc). He also served on the board of Emisphere Technologies and chaired the Special Committee in negotiating its sale to Novo Nordisk for $1.8 billion in December 2020. In addition, Tim is a co-founding investor and board member of Corino Therapeutics. His decades of board experience also include serving on audit, compensation and governance committees. Mr. McInerney received his B.S. in Pharmacy from St. John's University and also completed a post graduate residency in drug information systems at the New York University Medical Center.

Silence also announced that Board member, James Ede-Golightly, has decided to retire from the Board at the AGM in June 2025, having been a non-executive director and chair of the remuneration committee since 2019. James has been an instrumental member of the Silence Board as the Company has evolved into a clinical-stage company, delisted from the London Stock Exchange to become solely listed on Nasdaq, and transitioned to a U.S. domestic issuer.

Mr. Ross added, “The Board and I have the greatest respect and appreciation for James and his many contributions to Silence over the years, including his pivotal role in transitioning Silence from a UK centric company to a Nasdaq-listed global biotech. We wish him well and know he will continue to be very successful in the future.”

You May Also Be Interested In

• U.S. debt tops $40 trillion
• Guidewire ClaimCenter earns eight Celent awards across global regions
• Ocean Power Technologies revises fiscal 2026 results after audit